Atypical Placental Site Nodule Arising in a Postcesarean Section Scar: Case Report and Review of the Literature.

The distinction between benign and malignant trophoblastic lesions often presents a diagnostic challenge, even in entities with defined morphologic and immunohistochemical criteria. Lesions arising from chorionic-type intermediate trophoblast, namely placental site nodule (PSN) and epithelioid trophoblastic tumor (ETT), can be distinguished by existing criteria. However, a putative intermediate lesion termed "atypical placental site nodule" (APSN) has been described in the literature but is not well-classified. We present a case of APSN, along with a brief literature review, and we propose more definitive morphologic and immunohistochemical criteria for this entity, in order to facilitate easier diagnosis and gather more information regarding outcomes.

Role of P57KIP2 Immunohistochemical Expression in Histological Diagnosis of Hydatidiform Moles.

PURPOSE: To determine the significance of P57KIP2 immunohistochemistry expression in the histopathological diagnosis of hydatidiform mole. MATERIALS AND METHODS: Hydatidiform mole patients at King Chulalongkorn Memorial Hospital between January 1999 and December 2011 were recruited. Two gynecologic pathologists reviewed histopathologic slides to confirm diagnosis. Formalin-fixed, paraffin-embedded tissue sections were stained using a bstandard immunostaining system with monoclonal antibodies against P57KIP2 protein. Correlations among pathological features, immunohistochemical expression and clinical data were analyzed. RESULTS: One hundred and twenty-seven hydatidiform mole patients were enrolled. After consensus review, 97 cases were diagnosed as complet (CHM) and 30 cases as partial (PHM). Discordance between the first and final H and E diagnoses was found in 19 cases (14.9%, k= 0.578). Significant pathological features to classify the type of hydatidiform mole are central cisterns, trophoblastic proliferation, trophoblastic atypia, two populations of villi, fetal vessels and scalloped borders. After performing immunohistochemistry for P57KIP2, 107 cases were P57KIP2 negative and 20 cases positive. Discordant diagnoses between final H and E diagnosis and P57KIP2 immunohistochemistry was identified in 12 cases (9.4%). Sensitivity of final H and E diagnosis for CHM was 89.7%; specificity was 95.0%. PHM sensitivity and specificity of final H and E diagnosis was 95.0% and 89.7%, respectively. CONCLUSIONS: Histopathological diagnosis alone has certain limitations in accurately defining types of hydatidiform mole; P57KIP2 immunohistochemistry is practical and can be a useful adjunct to histopathology to distinguish CHM from non-CHM.

Nonchoriocarcinomatous Trophoblastic Tumors of the Testis: The Widening Spectrum of Trophoblastic Neoplasia.

Tumors of trophoblastic derivation other than choriocarcinoma are very rare in the testis but have been reported on occasion in association with other germ cell tumors. Their morphologic spectrum is analogous to the trophoblastic tumors of the female genital tract including epithelioid trophoblastic tumor (ETT) and placental site trophoblastic tumor (PSTT). Herein we report our experience with 8 cases of trophoblastic tumors of testicular origin that lacked the features of choriocarcinoma; these included 4 ETTs, 1 PSTT, 1 unclassified trophoblastic tumor (UTT), 1 partially regressed choriocarcinoma with a monophasic morphology, and 1 hybrid tumor showing a mixture of adenocarcinoma and a UTT. All tumors occurred in young men 19 to 43 years old. Five arose de novo within the testis (2 ETTs, 1 UTT, 1 regressing choriocarcinoma, and the hybrid tumor) as a component of mixed germ cell tumors, and 3 (2 ETTs and 1 PSTT) were found in metastatic sites after chemotherapy. The trophoblastic component was minor (5% to 10%) in 6 tumors but was 95% of 1 metastatic tumor (ETT) and 50% of the hybrid tumor. Other germ cell tumor elements were identified in all cases, most commonly teratoma. The ETTs consisted of nodules and nests of squamoid trophoblast cells showing abundant eosinophilic cytoplasm, frequent apoptotic cells, extracellular fibrinoid material, and positivity for p63 and negativity for human placental lactogen (HPL). The PSTT showed sheets of discohesive, pleomorphic, mononucleated trophoblast cells that invaded blood vessels with fibrinoid change and were p63 negative and HPL positive. The UTT showed a spectrum of small and large trophoblast cells, some multinucleated but lacking distinct syncytiotrophoblasts, and was patchily positive for both p63 and HPL. The hybrid tumor had ETT-like and adenocarcinomatous areas that coexpressed inhibin and GATA3 but were negative for p63 and HPL, leading to classification of the trophoblastic component as UTT. Seven of the patients were alive and well on follow-up (8 to 96 mo; median, 39 mo), whereas the patient with the hybrid tumor died of liver metastases at 2 years. Our study verifies that trophoblastic neoplasms often having the features of nonchoriocarcinomatous gestational trophoblastic tumors may arise from the testis, occur either in the untreated primary tumor or in metastases after chemotherapy, and should be distinguished from choriocarcinoma given what appears to be a less aggressive clinical course.

Classificação atual e tratamento da neoplasia trofoblástica gestacional / Present classification and therapy for gestational trophoblastic neoplasia

Neoplasia trofoblástica gestacional refere-se aos tipos de doença trofoblástica gestacional que necessitam de quimioterapia para obter a remissão completa. Na maioria dos casos, o tratamento apropriado resulta em taxa de sobrevida próxima de 100 porcento, com preservação da fertilidade. É importante identificar o grupo de pacientes com alto risco para falha do tratamento. A classificação atual, em dois grupos, é reconhecida pela Federação Internacional de Ginecologia e Obstetrícia, doentes de baixo risco, que podem ser curados com quimioterapia por agente único e doentes de alto risco, que necessitam de quimioterapia combinada e, em casos selecionados, de cirurgia e radioterapia coadjuvantes. A identificação de resistência da doença ao tratamento de primeira linha determina mudança de conduta, variável de acorco com a classificação. Novos agentes quimioterápicos, como os taxanes, são indicados para o tratamento de pacientes com doença resistente aos esquemas padrão de quimioterapia

The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment.

The classification of the International Federation of Obstetrics and Gynecology (FIGO) for Trophoblastic Disease was changed at the meeting in Washington in September 2000 by combining the basic FIGO anatomic staging with the modified World Health Organization (WHO) risk factor scoring system. This presentation outlines the new system and provides a critical evaluation of the issues that have been resolved and those that are still outstanding.

Tumor trofoblástico del lecho placentario: correlación clinicopatológica / Placenteral site trophoblastic tumor: Clinical pathologic correlation

Presentar la correlación clinicopatológica de seis pacientes con tumor trofoblástico del lecho placentario. El diagnóstico se realizó en 5 casos poshisterectomía y uno poscuretaje. Servicios obstétricos 9 y 6 de la Maternidad "Concepción Palacios". La edad promedio del grupo fue 32 años. En 3 casos (50 por ciento) el tumor tuvo su origen en embarazos molares y los otros 3 casos en abortos. Se realizó histerectomía en 5 casos (83,33 por ciento) y curetaje con observación estricta en 1 caso (16,66 pr ciento). Del total, 5 pacientes permanecen con criterios de curación. El diagnóstico, comportamiento biológico y planificación del tratamiento continúa y en la actualidad presentando dificultades

The classification of gestational trophoblastic disease: a critical review.

Gestational trophoblastic disease defines a group of conditions which arises from the fetal chorion. Two of the most important advances in the management of gestational trophoblastic disease have been the standardisation of terminology, and the concept of risk assignment based on classification or staging systems which allows rationalisation of treatment. Gestational trophoblastic disease is unique as the prognosis is dependent not only on the anatomic extent but also the presence of prognostic factors. A staging system similar to that used for other cancers does not apply to this disease because in most cases diagnosis is bases not on histology but on clinical or biochemical parameters. Metastatic spread to distant organs can occur early, even in the absence of disease in the uterus or pelvis. Staging in gestational trophoblastic disease must include prognostic factors in addition to anatomic extent of disease. Broadly there are two categories of classification in current use. The first is based on the usual staging system as in other cancers, with four stages of disease, but at the same time prognostic factors are incorporated. This has the important advantages of simplicity and uniformity with other staging systems. However the main pitfall is that no recommendations are made for treatment. The other broad category consists of risk tables, based on anatomic spread as well as prognostic factors. Here patients are assigned varying risk scores, with guidelines for multiagent chemotherapy at the outset in high-risk patients to minimise drug resistant disease. The ideal system would be one which has four stages of disease, so that comparison is easier, with recommendations for combination chemotherapy beyond a certain stage of disease.

Embarazo ectópico molar: presentación de un caso clínico / Molar ectopic pregnancy: presentation of a clinic case

Se describe el caso clínico de una paciente de 54 años de edad a quien se le practicó una laparotomía exploradora por tumor de ovario. El diagnóstico anátomopatológico perioperatorio fue mola ectópica tubárica. Se le practicó ooforosalpinguectomía del lado afectado. En vista de la persistencia de niveles elevados de Sub-Unidad Beta HCG, posteriormente se le practicó panhisterectomía sin evidencia de enfermedad macroscópica. El seguimiento fue clínico, con radiología de tórax y niveles de Hormona Gonadotrofina Coriónica (HCG). Los niveles de Sub-Unidad HCG fueron descendiendo progresivamente hasta normalizarse al octavo mes después de la segunda laparotomía. No hubo evidencia clínica ni radiológica de enfermedad recurrente en un año de seguimiento

[Trophoblastic disease in data from the Center for Trophoblastic Disease (diagnosis, therapy and results form 1955 to 1996). 1]. / Trofoblastická nemoc v materiálu Centra pro trofoblastickou nemoc (diagnostika, lécba a výsledky v letech 1955-1996) 1. cást.

The authors submit an analysis of the clinical pathological material of the nationwide trophoblastic diseases centre (CTN) from 1955-1996. It comprises a total of 5735 cases of trophoblastic disease (TN). This comprises choriocarcinoma (CH) 343 times, so far the largest group of CH verified by histological examination. It comprises furthermore proliferating mole (MP) 202 times complete hydatid mole (MHK) 360 times, partial hydatid mole (MHP) 1150 times persisting trophoblastic invasion (PTI) < 330 times, trophoblastic invasion (TI) 3220 times and persisting trophoblastic disease (PTN) 130 times. The author presents the morphological classification and diagnosis of TN proposed and used in CTN on a nationwide scale. It assessment the importance of different types of TN for their treatment and prognosis. The following units are defined: 1. Trophoblastic invasion, 2. Persisting trophoblastic invasion 3. Partial hydatid mole, 4. Complete hydatid mole, 5. Proliferating mole, 6. Choriocarcinoma which comprises five different types. In trophoblastic invasion the author describes its histological and cytological variability which formerly accounted for as much as 50% false positive diagnoses. Nowadays it is doubtful only in 5%. Persisting trophoblastic invasion was defined in CTN as a new special pathological unit of TN. Usually it recedes spontaneously. Nevertheless in 3% it was in CTN an indication for chemotherapy. In partial hydatid mole and in complete hydatid mole the morphological signs were, defined, which make their differential diagnosis possible which is essential for assessment of their prognosis. After complete hydatid mole choriocarcinoma developed in CTN in 6%. After partial hydatid mole the development of choriocarcinoma was not observed so far in CTN. Proliferating mole is defined in CTN in histological terms which makes its diagnosis from curettage possible. A malignant reversal of proliferating mole was recorded in CTN in 10%. Chemotherapy of proliferating mole was essential in 15%. The mortality rate of choriocarcinoma after proliferating mole declined from the original 85% to 3% and was zero during the last 10 years. According to the CTN classification there are five types of choriocarcinoma which differ markedly as to their biological properties and response to chemotherapy. The histological types of choriocarcinoma were defined on the basis of correlation with orthological trophoblasts of 7 to 20-day-old embryos. The types are: 1. Differentiated syncytiotrophoblastic choriocarcinoma, 2. Mixed differentiated choriocarcinoma, 3. Differentiated cytotrophoblastic choriocarcinoma, 4. Non-differentiated choriocarcinoma, 5. Dissociated choriocarcinoma. Types 1 and 2 respond excellently to chemotherapy and produce high values of hCG. Type 3, 4 and 5 are not very sensitive to chemotherapy or even resistant and produce low values of hCG. Some require primary surgery. They are histologically defined forms of so-called Placental Site Trophoblastic Tumours.

Histologic classification and staging of gestational trophoblastic disease.

Gestational trophoblastic disease (GTD) forms a heterogeneous group of interrelated lesions which are characterized by an abnormal proliferation of the different types of trophoblastic epithelium. Complete hydatidiform moles represent a noninvasive placental disease that is characterized by hydropic swelling of the chorionic villi with marked trophoblastic proliferation. The partial mole contains two populations of villi: one of normal size, the other hydropic with less marked trophoblastic hyperplasia. The risk of developing persistent GTD is very low. Choriocarcinomas represent an avillous invasive proliferation of trophoblastic cells surrounded by necroses and hemorrhages displaying a dimorphic pattern with early vascular invasion and hematogeneous metastatic spread. Placental site trophoblastic tumor (PSTT) resembles the rarest form of GTD. In its cellular composition, PSTT preferentially contains intermediate trophoblastic cells with typically positive hPL-immunostaining. Mostly, PSTT's are benign tumors, but malignant cases are well known. Miscelleanous forms of GTD include the exaggerated placental site and the placental site nodule or plaque. Both lesions are proliferations of the intermediate trophoblast. Staging of GTD should only be applied in cases of persistent disease. All different staging systems, including the revised FIGO system, the classification of the National Institute of Health (NIH), the WHO scoring system and the currently adopted TNM-system are able to define high risk patients.